Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | RAD51 | Q06609 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAD1 | O60671 | 1/20 | 0.46 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.46 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.46 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192147 | 1.00 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL3198897 | 0.93 | MEN1 (0.60) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL4591467 | 0.93 | MEN1 (0.60) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL3198907 | 0.93 | MEN1 (0.60) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL3188185 | 0.85 | MAPT (0.49) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL3188169 | 0.85 | MAPT (0.49) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL3186852 | 0.83 | KMT2A (0.58) | ALDH1A1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL3186839 | 0.83 | KMT2A (0.58) | ALDH1A1KMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL4591257 | 0.82 | ALDH1A1 (0.58) | ALDH1A1KMT2AGAAMAPTSMN1; SMN2 | |
| SCHEMBL3204323 | 0.80 | KMT2A (0.64) | ALDH1A1KMT2AMEN1L3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | claimed |
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-06 | — | — | US | claimed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | ALDH1A1 3191/4885KMT2A 1756/4885MEN1 1676/4885 |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | ALDH1A1 3191/4885KMT2A 1756/4885MEN1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.